End-to-end approach for the characterization and control of product-related impurities in T cell bispecific antibody preparations
Antibody-based T cell-activating biologics are promising therapeutic medicines being developed for a number of indications, mainly in the oncology field. Among those, T cell bispecific antibodies are designed to bind one tumor-specific antigen and the T cell receptor at the same time, leading to a r...
Saved in:
Main Authors: | Laurent Larivière (Author), Julia Eva Krüger (Author), Thomas von Hirschheydt (Author), Tilman Schlothauer (Author), Katharine Bray-French (Author), Martin Bader (Author), Valeria Runza (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bispecific antibodies in cancer immunotherapy
by: Eva Dahlén, et al.
Published: (2018) -
Bispecific antibodies for viral immunotherapy
by: Elisabeth K. Nyakatura, et al.
Published: (2017) -
Bispecific Antibodies Progression in Malignant Melanoma
by: Juan Tang, et al.
Published: (2022) -
A pivotal decade for bispecific antibodies?
by: Marlena Surowka, et al.
Published: (2024) -
Bispecific antibodies: design, therapy, perspectives
by: Sedykh SE, et al.
Published: (2018)